GNPX vs. AYTU, SLGL, NRBO, MEIP, IBIO, SNSE, LUMO, SYBX, KALA, and GLYC
Should you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Aytu BioPharma (AYTU), Sol-Gel Technologies (SLGL), NeuroBo Pharmaceuticals (NRBO), MEI Pharma (MEIP), iBio (IBIO), Sensei Biotherapeutics (SNSE), Lumos Pharma (LUMO), Synlogic (SYBX), KALA BIO (KALA), and GlycoMimetics (GLYC). These companies are all part of the "pharmaceutical preparations" industry.
Genprex (NASDAQ:GNPX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.
In the previous week, Genprex had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 3 mentions for Genprex and 2 mentions for Aytu BioPharma. Genprex's average media sentiment score of 0.96 beat Aytu BioPharma's score of 0.43 indicating that Genprex is being referred to more favorably in the media.
14.1% of Genprex shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 11.5% of Genprex shares are owned by insiders. Comparatively, 2.8% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Genprex has a net margin of 0.00% compared to Aytu BioPharma's net margin of -14.60%. Aytu BioPharma's return on equity of -31.31% beat Genprex's return on equity.
Aytu BioPharma has higher revenue and earnings than Genprex.
Genprex currently has a consensus target price of $10.00, indicating a potential upside of 221.54%. Aytu BioPharma has a consensus target price of $5.00, indicating a potential upside of 58.73%. Given Genprex's higher probable upside, equities analysts plainly believe Genprex is more favorable than Aytu BioPharma.
Aytu BioPharma received 56 more outperform votes than Genprex when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 65.25% of users gave Genprex an outperform vote.
Genprex has a beta of -0.54, indicating that its stock price is 154% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.23, indicating that its stock price is 223% less volatile than the S&P 500.
Summary
Aytu BioPharma beats Genprex on 7 of the 13 factors compared between the two stocks.
Get Genprex News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
